Biotechnology · Norcross, Georgia, United States
$4.87
+8.22% (+$0.37)2026-07-09
Smart-Money SignalNeutral · 52/100— Insiders are net sellers over 90 days (-$262K, 14 sales vs 7 buys)
Net Income-$5.0M
EPS$-0.08
Market Cap$320.7M
Price Performance
Historical data including institutional events
Company Profile
J
Joel Lewis
CEO & Executive Director
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
- Founded
- 2000
- Employees
- 15
- Headquarters
- Norcross, Georgia, United States
- Website
- galectintherapeutics.com
Peer ComparisonRevenue ($B)
▾Loading company sections...